ams Provides Sensor Technology for Medical Technology Startup midge medical to Develop Rapid Test Device for COVID-19 (SARS-C...
04 Agosto 2020 - 9:50AM
Dow Jones News
ams (SIX: AMS), a leading worldwide supplier of high performance
sensor solutions, provides the latest sensor technology to midge
medical, a German medical technology startup from Berlin, to
develop a disruptive technology for science-backed rapid genetic
and blood testing in a home and professional healthcare environment
at a lower cost. midge medical's current focus is on developing a
pocket-sized COVID-19 (SARS-CoV-2) genetic test. Test results can
be read-out using a smartphone in as little as 15 minutes. ams and
midge medical's collaboration aims to provide a technology with the
potential to move the current market forward.
A specifically developed sensor system based on the ams AS7341L
spectral sensor solution allows spectrally resolved read out of
amplified COVID-19 (SARS-CoV-2) virus particles, strengthening ams'
position in delivering high-quality consumer health
diagnostics.
Helping fight the COVID-19 (SARS-CoV-2) pandemic
The current COVID-19 (SARS-CoV-2) crisis has made it clear:
experts suggest there is an urgent need for frequent high-quality
testing of symptomatic and asymptomatic people to manage the
current pandemic and future crises. The new test addresses the
unmet need of frequent, affordable, rapid and mass testing during
the pandemic.
A promising cooperation
"The unique diagnostic vision of midge medical, in combination
with ams' highly-performant and sensitive spectral sensors, has
resulted in a miniaturized readout at a fraction of the cost of
currently available systems, enabling decentralized testing at home
and in professional healthcare environments. The midge smartphone
app delivers instant results that can be displayed on any
authorized smartphone," said Jennifer Zhao, Executive Vice
President for Advanced Optical Sensors Division at ams.
"We are pleased to collaborate with ams as a globally known
strong partner to bring this low cost type of test to the market.
By enabling broad and frequent testing, even in the absence of
immunization, going back to an almost normal life will be possible
again," added Michael Diebold, CEO at midge medical.
For more information on the ams AS7341L spectral sensor, please
visit ams.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20200804005576/en/
CONTACT: Amy Flécher
Vice President Marketing Communications
press@ams.com
ams.com
SOURCE: ams
Copyright Business Wire 2020
(END) Dow Jones Newswires
August 04, 2020 08:35 ET (12:35 GMT)